Alluvi, previously BI 4744, represents a significant advance in obesity care. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling https://kingbookmark.com/story22202504/alluvi-a-comprehensive-dive-into-retatrutide-s-possibilities